News headlines about AbbVie (NYSE:ABBV) have been trending somewhat positive this week, according to Accern Sentiment. Accern identifies negative and positive media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. AbbVie earned a coverage optimism score of 0.17 on Accern’s scale. Accern also gave headlines about the company an impact score of 46.7158338082093 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Here are some of the news headlines that may have effected Accern’s analysis:
Shares of NYSE ABBV opened at $89.78 on Friday. The company has a debt-to-equity ratio of 6.07, a quick ratio of 1.18 and a current ratio of 1.28. AbbVie has a 52-week low of $63.12 and a 52-week high of $125.86. The company has a market capitalization of $142,568.22, a PE ratio of 16.03, a PEG ratio of 0.85 and a beta of 1.61.
AbbVie (NYSE:ABBV) last released its earnings results on Friday, January 26th. The company reported $1.48 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.44 by $0.04. AbbVie had a net margin of 18.82% and a return on equity of 158.15%. The company had revenue of $7.74 billion for the quarter, compared to the consensus estimate of $7.53 billion. During the same quarter in the previous year, the company earned $1.20 EPS. AbbVie’s quarterly revenue was up 13.9% compared to the same quarter last year. equities research analysts expect that AbbVie will post 7.51 EPS for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, May 15th. Shareholders of record on Friday, April 13th will be issued a dividend of $0.96 per share. This is an increase from AbbVie’s previous quarterly dividend of $0.71. The ex-dividend date of this dividend is Thursday, April 12th. This represents a $3.84 annualized dividend and a yield of 4.28%. AbbVie’s dividend payout ratio is presently 50.71%.
AbbVie declared that its board has authorized a stock buyback program on Thursday, February 15th that allows the company to buyback $10.00 billion in outstanding shares. This buyback authorization allows the company to reacquire shares of its stock through open market purchases. Stock buyback programs are usually an indication that the company’s management believes its stock is undervalued.
Several analysts have weighed in on the stock. Barclays reduced their target price on shares of AbbVie from $120.00 to $102.00 and set an “equal weight” rating on the stock in a research report on Thursday. BMO Capital Markets restated a “sell” rating and issued a $80.00 price objective on shares of AbbVie in a report on Thursday. ValuEngine lowered shares of AbbVie from a “strong-buy” rating to a “buy” rating in a report on Wednesday, March 28th. Jefferies Group set a $125.00 price objective on shares of AbbVie and gave the stock a “buy” rating in a research note on Friday, March 23rd. Finally, Evercore ISI reissued a “buy” rating and issued a $144.00 target price on shares of AbbVie in a report on Monday, January 29th. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $117.38.
In related news, CFO William J. Chase sold 70,928 shares of the stock in a transaction dated Thursday, March 1st. The shares were sold at an average price of $117.18, for a total transaction of $8,311,343.04. Following the completion of the transaction, the chief financial officer now owns 203,391 shares in the company, valued at $23,833,357.38. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, VP Robert A. Michael sold 992 shares of the stock in a transaction dated Tuesday, February 20th. The shares were sold at an average price of $120.31, for a total transaction of $119,347.52. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 211,197 shares of company stock worth $24,585,575. Corporate insiders own 0.07% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This report was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this report on another site, it was copied illegally and republished in violation of United States and international copyright legislation. The legal version of this report can be viewed at https://www.dispatchtribunal.com/2018/04/08/abbvie-abbv-getting-somewhat-positive-news-coverage-analysis-finds.html.
AbbVie Inc discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company offers HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; IMBRUVICA, an oral therapy for the treatment of patients with chronic lymphocytic leukemia; and VIEKIRA PAK, an interferon-free therapy, with or without ribavirin, for the treatment of adults with genotype 1 chronic hepatitis C.
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.